File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1159/000072670
- Scopus: eid_2-s2.0-0141649457
- PMID: 14512704
- WOS: WOS:000185887800009
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Augmented pulmonary vascular and venous constrictions to N G-nitro-L-arginine methyl ester in rats with monocrotaline-induced pulmonary hypertension
Title | Augmented pulmonary vascular and venous constrictions to N G-nitro-L-arginine methyl ester in rats with monocrotaline-induced pulmonary hypertension |
---|---|
Authors | |
Keywords | Blood pressure Cardiac output Nitric oxide Pulmonary vascular resistance Pyrrolizidine alkaloid Systemic vascular resistance |
Issue Date | 2003 |
Publisher | S Karger AG. The Journal's web site is located at http://www.karger.com/PHA |
Citation | Pharmacology, 2003, v. 69 n. 3, p. 164-170 How to Cite? |
Abstract | The hemodynamic effects of NG-nitro-L-arginine methyl ester (L-NAME, inhibitor of nitric oxide (NO) synthase) were examined in thiobutabarbital-anesthetized control- rats and rats with monocrotaline-induced pulmonary hypertension. L-NAME (1-16 mg/kg i.v.) increased mean arterial pressure, systemic vascular resistance, venous resistance and pulmonary vascular resistance, and decreased cardiac output in both the control and pulmonary hypertensive rats. Relative to the controls, L-NAME (16 mg/kg) caused a smaller increase (≈50% of control) in mean arterial pressure in the pulmonary hypertensive rats, but greater increases in venous (≈200%) as well as pulmonary vascular (≈400%) resistances and a greater decrease in cardiac output (≈140%). The results show that NO is an important dilator within the arterial, venous and pulmonary circulation; its pulmonary and venous dilator roles are augmented in pulmonary hypertension. Copyright © 2003 S. Karger AG, Basel. |
Persistent Identifier | http://hdl.handle.net/10722/171301 |
ISSN | 2023 Impact Factor: 2.9 2023 SCImago Journal Rankings: 0.679 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Leung, SWS | en_US |
dc.contributor.author | Cheng, X | en_US |
dc.contributor.author | Lim, SL | en_US |
dc.contributor.author | Pang, CCY | en_US |
dc.date.accessioned | 2012-10-30T06:13:16Z | - |
dc.date.available | 2012-10-30T06:13:16Z | - |
dc.date.issued | 2003 | en_US |
dc.identifier.citation | Pharmacology, 2003, v. 69 n. 3, p. 164-170 | en_US |
dc.identifier.issn | 0031-7012 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/171301 | - |
dc.description.abstract | The hemodynamic effects of NG-nitro-L-arginine methyl ester (L-NAME, inhibitor of nitric oxide (NO) synthase) were examined in thiobutabarbital-anesthetized control- rats and rats with monocrotaline-induced pulmonary hypertension. L-NAME (1-16 mg/kg i.v.) increased mean arterial pressure, systemic vascular resistance, venous resistance and pulmonary vascular resistance, and decreased cardiac output in both the control and pulmonary hypertensive rats. Relative to the controls, L-NAME (16 mg/kg) caused a smaller increase (≈50% of control) in mean arterial pressure in the pulmonary hypertensive rats, but greater increases in venous (≈200%) as well as pulmonary vascular (≈400%) resistances and a greater decrease in cardiac output (≈140%). The results show that NO is an important dilator within the arterial, venous and pulmonary circulation; its pulmonary and venous dilator roles are augmented in pulmonary hypertension. Copyright © 2003 S. Karger AG, Basel. | en_US |
dc.language | eng | en_US |
dc.publisher | S Karger AG. The Journal's web site is located at http://www.karger.com/PHA | en_US |
dc.relation.ispartof | Pharmacology | en_US |
dc.subject | Blood pressure | - |
dc.subject | Cardiac output | - |
dc.subject | Nitric oxide | - |
dc.subject | Pulmonary vascular resistance | - |
dc.subject | Pyrrolizidine alkaloid | - |
dc.subject | Systemic vascular resistance | - |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Blood Pressure - Drug Effects | en_US |
dc.subject.mesh | Dose-Response Relationship, Drug | en_US |
dc.subject.mesh | Hypertension, Pulmonary - Drug Therapy - Metabolism - Physiopathology | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Monocrotaline | en_US |
dc.subject.mesh | Ng-Nitroarginine Methyl Ester - Pharmacology | en_US |
dc.subject.mesh | Nitric Oxide - Antagonists & Inhibitors | en_US |
dc.subject.mesh | Rats | en_US |
dc.subject.mesh | Rats, Sprague-Dawley | en_US |
dc.subject.mesh | Vascular Resistance - Drug Effects | en_US |
dc.subject.mesh | Vasoconstriction - Drug Effects | en_US |
dc.title | Augmented pulmonary vascular and venous constrictions to N G-nitro-L-arginine methyl ester in rats with monocrotaline-induced pulmonary hypertension | en_US |
dc.type | Article | en_US |
dc.identifier.email | Leung, SWS:swsleung@hku.hk | en_US |
dc.identifier.authority | Leung, SWS=rp00235 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1159/000072670 | en_US |
dc.identifier.pmid | 14512704 | - |
dc.identifier.scopus | eid_2-s2.0-0141649457 | en_US |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-0141649457&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 69 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.spage | 164 | en_US |
dc.identifier.epage | 170 | en_US |
dc.identifier.isi | WOS:000185887800009 | - |
dc.publisher.place | Switzerland | en_US |
dc.identifier.scopusauthorid | Leung, SWS=24540419500 | en_US |
dc.identifier.scopusauthorid | Cheng, X=37044433300 | en_US |
dc.identifier.scopusauthorid | Lim, SL=7404080728 | en_US |
dc.identifier.scopusauthorid | Pang, CCY=7201425219 | en_US |
dc.identifier.issnl | 0031-7012 | - |